Accredited clinical laboratory and life sciences company

2016

Repak R, Kohoutova D, Podhola M, Rejchrt S, Minarik M, Benesova L, Lesko M, Bures J.
The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature.
Gastrointest Endosc. 2016 Jun 23. pii: S0016-5107(16)30269-3. doi: 10.1016/j.gie.2016.06.023. [Epub ahead of print], PMID: 27343414

Minarikova P, Benesova L, Halkova T, Belsanova B, Suchanek S, Cyrany J, Tuckova I, Bures J, Zavoral M, Minarik M.
Longitudinal molecular characterization of endoscopic specimens from colorectal lesions.
World J Gastroenterol. 2016 May 28;22(20):4936-45. doi: 10.3748/wjg.v22.i20.4936., PMID:27239120

Svaton M, Fiala O, Pesek M, Bortlicek Z, Minarik M, Benesova L, Topolcan O.
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
Anticancer Res. 2016 Mar;36(3):1077-82., PMID: 26977001

Fiala O, Pesek M, Finek J, Racek J, Minarik M, Benesova L, Bortlicek Z, Sorejs O, Kucera R, Topolcan O.
Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
Neoplasma. 2016;63(3):471-6. doi: 10.4149/318_151001N512.

Fiala O, Pesek M, Finek J, Minarik M, Benesova L, Sorejs O, Svaton M, Bortlicek Z, Kucera R, Topolcan O.
Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.
Anticancer Res. 2016, 36, 455-460.

Fiala O, Pesek M, Finek J, Svaton M, Minarik M, Benesova L, Bortlicek Z, Kucera R, Topolcan O.
Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene.
Anticancer Res. 2016, 36, 447-453.